Study of KITE-363 for autoimmune nerve diseases
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these conditions: multiple sclerosis (relapsing or progressive types), myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy.
- Your condition must still be active despite trying at least one or two standard treatments.
- You must agree to use birth control if applicable.
- You cannot have had a stem cell or organ transplant in the past.
- You cannot have any other nerve disorder that might affect the results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.